KPTI Stock Analysis: Buy, Sell, or Hold?
KPTI - Karyopharm Therapeutics Inc.
$9.31
-0.34 (-3.52%)
▼
5d:
+2.31%
30d:
+14.09%
90d:
+71.14%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When KPTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KPTI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KPTI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KPTI is currently trading at $9.31, which is considered slightly high relative to its 30-day fair value range of $8.25 to $9.53.
Technical Outlook: Technically, KPTI is in a uptrend. Immediate support is located at $8.43, while resistance sits at $9.98. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.50 (+39.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KPTI is in a uptrend. Immediate support is located at $8.43, while resistance sits at $9.98. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (25th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.50 (+39.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$8.25 -
$9.53
Company Quality Score
54/100
(HOLD)
Options IV Signal
25th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
69.6%
All Signals
- BULLISH: Options cheap (IV 25th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 39.9% below Wall St target ($13.50)
Trading Range Analysis
30-Day Trading Range
$8.25 -
$9.53
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$1.73
(18.5%)
Support & Resistance Levels
Support Level
$8.43
Resistance Level
$9.98
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.97
Wall Street Target
$13.50
(+39.9%)
Revenue Growth (YoY)
16.8%
Profit Margin
-129.0%
Share & Embed Analysis
Last updated: June 24, 2026 1:46 PM ET
Data refreshes hourly during market hours. Next update: 2:46 PM
Data refreshes hourly during market hours. Next update: 2:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KPTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Reshma Rangwala
SELL
449 shares
2026-04-21
Kristin Abate
SELL
50 shares
2026-01-28
Kristin Abate
SELL
265 shares
2026-01-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 63 BUY |
